Drug Trial Radar · NCT04485481
Single and Multiple Ascending Dose Study of ADX-914 in Healthy Adult Volunteers
Last checked: Nov 19, 2026Latest source record: Jul 28, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Sep 8, 2020
Primary completion
Jan 12, 2022
Study completion Jan 12, 2022
Sponsor
- Lead sponsor
- Q32 Bio Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 24, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 50 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
A two (2) part study to evaluate the safety, tolerability and PK of ADX-914
Conditions
- Safety Issues
Interventions
ADX-914Drug
Single dose from 0.1mg/kg to TBD
PlaceboDrug
Matching single dose placebo
ADX-914Drug
Multiple dose from TBD to TBD
PlaceboDrug
Matching multiple dose placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with adverse eventsTime frame: Screening to end of study, up to 18 weeks
- Number of subjects with Physical exam findingsTime frame: Screening to end of study, up to 18 weeks
- Number of subjects with Clinical safety lab changesTime frame: Screening to end of study, up to 18 weeks
- Number of subjects with Systolic blood pressure changesTime frame: Screening to end of study, up to 18 weeks
- Number of subjects with Heart rate changesTime frame: Screening to end of study, up to 18 weeks
- Number of subjects with 12 Lead ECG changesTime frame: Screening to end of study, up to 18 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nucleus Network
Melbourne, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.